ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
NCT ID: NCT00425672
Last Updated: 2018-12-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
15 participants
INTERVENTIONAL
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase I/II trial is studying the safety of ONTAK and its possible side effects to see how well it works in treating patients with advanced breast cancer that did not respond to previous treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
NCT00228358
Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery
NCT00015886
Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer
NCT00212095
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
NCT02658812
Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer
NCT00206453
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To evaluate the safety of ONTAK infusion in patients with advanced refractory breast cancer.
II. To evaluate the effect of ONTAK administration on peripheral blood T-regulatory cells.
SECONDARY OBJECTIVES:
I. To evaluate the incidence of IL-2R expression in tumor samples and investigate the correlation of tumor IL-2R expression and tumor response to ONTAK therapy.
II. To evaluate levels of circulating sIL-2R before and after ONTAK therapy. III. To evaluate the effect of ONTAK on endogenous tumor specific immunity. IV. To evaluate the potential anti-tumor effects of ONTAK in patients with advanced refractory breast cancer.
OUTLINE:
Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
ONTAK
Given IV
flow cytometry
Correlative studies
immunohistochemistry staining method
Correlative studies
enzyme-linked immunosorbent assay
Correlative studies
laboratory biomarker analysis
Correlative studies
protein expression analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ONTAK
Given IV
flow cytometry
Correlative studies
immunohistochemistry staining method
Correlative studies
enzyme-linked immunosorbent assay
Correlative studies
laboratory biomarker analysis
Correlative studies
protein expression analysis
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Progressive or relapsed disease following standard therapy
* Patients must have measurable disease that can include, but is not limited to bone; specifically, patients must have measurable extraskeletal disease that can be accurately measured in at least one dimension as \>= 20 mm with conventional CT techniques or \>= 10 mm with spiral CT scan; measurable (bi-dimensional) chest wall disease will also be allowed
* Patients must be at least 14 days out from last cytotoxic chemotherapy; patients on bisphosphonates are eligible
* White blood cell count (WBC) \> 3.0 THOU/ul
* ANC \> 1.0 THOU/ul
* Platelets \>= 100 THOU/ul
* Serum creatinine =\< 2.0 mg/dL or creatinine clearance (calculated) \>= 60 ml/min
* ALT/AST =\< 2.0 x upper limit of normal
* Total bilirubin =\< 1.5 x upper limit of normal
* Albumin \>= 3.0 g/dL
* Subjects must have a Performance Status Score (ECOG Scale) =\< 2
* Subjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment
* Men and women of reproductive ability must agree to contraceptive use during the study and for 1month after ONTAK treatment is discontinued
Exclusion Criteria
* Known history of hypersensitivity to diphtheria toxin or IL-2
* Active autoimmune disease
* Known history of pulmonary disease except controlled asthma
* History of or pre-existing, cardiovascular disease as defined by New York Heart Association (NYHA) Class III-IV categorization
* Pregnant or breast-feeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University of Washington
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mary (Nora) Disis
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lupe Salazar
Role: PRINCIPAL_INVESTIGATOR
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2010-00800
Identifier Type: REGISTRY
Identifier Source: secondary_id
127
Identifier Type: OTHER
Identifier Source: secondary_id
6308 (FH/UWCC ID)
Identifier Type: -
Identifier Source: org_study_id
NCT00364208
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.